Why ImmunityBio Stock Is Skyrocketing Again Today

ImmunityBio reported that Anktiva trial enrollment for non‑muscle‑invasive bladder cancer exceeded expectations, positioning the company to potentially submit a biologics license application to the FDA by year‑end, and preliminary 2025 results showed Anktiva sales grew over 700%. The firm also disclosed 100% disease control in the first four Non‑Hodgkin lymphoma patients treated with its CAR‑NK therapy, while recent regulatory wins (Saudi approval and a step toward EU marketing approval) helped drive a 127% weekly stock surge; the company carries roughly $800m in net cash and a ~$5.3bn market capitalization. These developments materially de‑risk near‑term commercial momentum for Anktiva and increase optionality around next‑generation immunotherapies, though volatility and execution risk remain.

Analysis

Market structure: IBRX is the primary winner—Anktiva's accelerated uptake (management cites >700% 2025 sales growth) and a possible BLA submission by year-end can re-price a $5.3B market cap company with ~$800M net cash into a commercial oncology multiple. Short-term winners also include CDMOs and next‑gen immunotherapy peers; incumbent NMIBC suppliers face share loss risk if Anktiva gains label expansion. The demand signal is strong (rapid enrollment, international approvals), so pricing power and capacity constraints matter in 6–18 months as commercialization scales.

Risk assessment: Tail risks include FDA denial, safety events in broader CAR‑NK cohorts beyond the initial 4 patients, partner/manufacturing failures, or payer rejection of high prices—each could halve valuation quickly. Immediate (days) effect is elevated volatility; short term (weeks–months) centers on BLA submission/filings and quarterly sales cadence; long term (1–3 years) depends on multi‑indication adoption and durable CAR‑NK efficacy. Hidden dependency: revenue concentration on Anktiva and small early CAR‑NK sample sizes inflate binary outcomes.

Trade implications: Direct: establish a measured long (2–3% portfolio) or buy defined‑risk LEAP call spreads (9–12 month, ~0.35–0.45 delta buy / sell 30–40% higher strike) to target asymmetric upside into year‑end BLA. Pair: long IBRX / short IBB (or XBI) to isolate idiosyncratic upside; size 1–2% net. Short‑term: sell 30–60 day call spreads only on IV spikes >40% post‑news; protect with 90‑day 10–15% OTM puts (0.5% portfolio) around catalyst windows.

Contrarian angles: Consensus ignores sample‑size risk (4 patients) and commercialization execution risk—the 127% weekly rally likely overstates sustainable intrinsic value. Historical parallels show rapid runups on early efficacy often retrace after payer pushback or safety signals; use defined‑risk structures and explicit stop‑losses. If sales growth decelerates below +100% YoY or cash falls < $500M, re-evaluate to exit.

Key Decisions for Investors

• Establish a 2–3% long equity position in IBRX on a pullback of up to 20% from current levels; set a hard stop‑loss at 30% and trim half at +50% and remainder at +100% to lock gains ahead of BLA-related catalysts (time horizon: 3–12 months).
• Purchase a defined‑risk bullish LEAP call spread (9–12 month expiry) sized ~0.5% of portfolio: buy ~0.35–0.45 delta calls and sell calls 30–40% higher to fund cost; hold into potential BLA submission by year‑end, max loss = premium paid.
• Implement a pair trade: long IBRX (1–2% portfolio) and short equal dollar IBB or XBI to neutralize sector beta; rebalance on major readouts or if IBRX share price moves ±40% from entry.
• Protect downside around catalysts: allocate 0.5% portfolio to 90‑day 10–15% OTM puts before major regulatory windows, and sell 30–60 day call spreads only when implied volatility exceeds 40% to harvest premium; reduce position if pro forma net cash drops below $500M or quarterly sales growth decelerates to <100% YoY.